生命科学资讯

Lilly links up with InduPro in next-gen cancer treatment deal worth up to $950M

Pulmocide calls curtains on phase 3 antifungal trial over low response, higher mortality rate

Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus’ replication

Staar Surgical's takeover saga ends as shareholder revolt stops Alcon’s attempted merger deal

Soley secures $200M series C to push AML cell stress drug into clinic

Rakuten lights path to 2028 FDA filing with fresh $100M raise

Amgen dances with Disco in $618M cancer target pact

Fierce Biotech Fundraising Tracker '26: Soley sees $200M series C; Rakuten rakes in $100M

Hutchmed heats up autoimmune race with phase 3 win, teeing up China filing

GSK's 'functional cure' for hep B proves worth in phase 3 trials setting up approval push

BrainSpace garners FDA clearance for brain fluid management system

3 biopharma CEOs explain why they are 'authentically optimistic' for 2026

Arrowhead takes aim at obesity market with early data on dual gene silencing assets

In Structure licensing deal, Roche commits $100M to shore up GLP-1 position

Amgen stitches new acquisition worth up to $840M for UK biotech and its cancer programs

Bright Minds shines with phase 2 win for anti-seizure serotonin receptor activator

Boehringer continues kidney disease dealmaking run with $120M Variant Bio pact

FDA cites severe liver injury risk, unclear benefit behind Sanofi's MS drug rejection

UK biotech eyes $1B deal to enable eye gene therapy to be delivered in doctors' offices

Biobeat Technologies drums up $50M for its cuffless blood pressure monitor